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Chronic migraine (CM), a highly disabling condition
affecting 2-3% of the general population, represents a
difficult-to-treat disorder for its unclear pathophysiology,
complex comorbidities, and disappointing response to
available pharmacological treatments [1]. High quality
evidence (≥2 RCTs) recommends the prophylactic use
of onabotulinum toxin A (155-195 IU) and topiramate
(100 mg) in CM, while lower quality evidence (1 RCT)
supports the treatment with sodium valproate (800-1500
mg), gabapentin (2400 mg) and tizanidine (18 mg) [2].
Amitriptyline, memantine, zonisamide and pregabalin
may also be of help in CM but their use has been sug-
gested only in open studies [2]. CM patients may show
poor or no response to preventative therapies. The con-
sensus statement of the European Headache Federation
(EHF) defines CM refractory to treatment (rCM) when
it does not respond to adequate dosages of at least 3
drugs from the classes of beta-blockers, anticonvulsants,
tricyclics, onabotulinum toxin A and others (e.g., flunar-
izine, candesartan) for at least 3 months each, in
absence of medication overuse [3]. This rCM definition
has been questioned by some authors who stressed the
need of using drugs from different classes, not limited
to 3, before making rCM diagnosis [4]. Labeling a
patient as affected by rCM may profoundly modify his/
her life with heavy psychological, social, work and med-
ico-legal consequences, potentially leading to expensive
and still unsatisfying surgical procedures such as occipital
nerve stimulation [5]. We point out the risk that the cur-
rent rCM EHF definition could indeed also include
pseudo-refractory CM patients, due to potential bias:
firstly, a significant proportion of CM patients may spon-
taneously reverse to episodic migraine, as clearly evi-
denced in population-based study [6]; secondly, rCM
patients may present underlying psychiatric disturbances
(e.g., personality disorders) not easily recognized, classified
and treated by headache specialists; thirdly, rCM diagnosis
could be biased by unproven evidence as current rCM cri-
teria do not specify who should attest patient’s previous
headache history (theoretically self-reported or stated by
unqualified physicians). We suggest that 1) rCM is prob-
ably more rare than presently stated; 2) before formulating
a diagnosis of rCM, psychiatric disorders should be care-
fully ruled out by appropriate and thorough psychiatric
investigations; 3) when assessing CM patient’s past medi-
cal history, only clinical data coming from certified head-
ache centers should be considered; 4) CM patients should
be followed up for an adequate period of time before mak-
ing a definite rCM diagnosis.
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